| 3.98 0.59 (17.4%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.06 |
1-year : | 7.08 |
| Resists | First : | 5.19 |
Second : | 6.06 |
| Pivot price | 3.82 |
|||
| Supports | First : | 3.53 |
Second : | 2.51 |
| MAs | MA(5) : | 3.73 |
MA(20) : | 3.55 |
| MA(100) : | 2.89 |
MA(250) : | 2.81 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2  |
| %K %D | K(14,3) : | 42.8 |
D(3) : | 43.2 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 5.19 | Low : | 2.33 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ELYM ] has closed below upper band by 44.2%. Bollinger Bands are 325.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.16 - 4.19 | 4.19 - 4.21 |
| Low: | 3.28 - 3.3 | 3.3 - 3.32 |
| Close: | 3.94 - 3.98 | 3.98 - 4.02 |
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
Thu, 25 Apr 2024
Short Interest in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Increases By 4,453.8% - MarketBeat
Wed, 24 Apr 2024
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Position Boosted by BML Capital Management LLC - MarketBeat
Tue, 23 Apr 2024
Eliem Therapeutics (NASDAQ:ELYM) Shares Up 0.5% - MarketBeat
Mon, 15 Apr 2024
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and ... - PR Newswire
Thu, 11 Apr 2024
WilmerHale Advises Eliem Therapeutics in Acquisition of Tenet Medicines and Concurrent $120 Million Private ... - WilmerHale
Thu, 11 Apr 2024
Nasdaq Jumps 250 Points; Crude Oil Down 1% - Aptevo Therapeutics (NASDAQ:APVO), Eliem Therapeutics (NASDA - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 26.1 (%) |
| Held by Institutions | 67.2 (%) |
| Shares Short | 13 (K) |
| Shares Short P.Month | 11 (K) |
| EPS | -1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -11 % |
| Return on Equity (ttm) | -29.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | -3.07 |
| PEG Ratio | 0 |
| Price to Book value | 1.02 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|